As of June 30, 2026, Alebund Pharmaceuticals (Jiangsu) Limited Class H carries a market capitalization of 15.61B, placing it among publicly traded companies globally. Its enterprise value stands at 14.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15.61B |
| Enterprise Value | 14.66B |
Alebund Pharmaceuticals (Jiangsu) Limited Class H's next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, Alebund Pharmaceuticals (Jiangsu) Limited Class H has 339.85M shares outstanding.
| Shares Outstanding | 339.85M |
These figures are as of June 30, 2026.
| PB Ratio | 9.59 |
| P/TBV Ratio | 9.65 |
As of June 30, 2026, Alebund Pharmaceuticals (Jiangsu) Limited Class H maintains a current ratio of 9.81, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.81 |
| Quick Ratio | 9.65 |
| Debt / Equity | 40.94 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 162.00 |
These figures are as of the close on November 17, 2026.
| 50-Day Moving Average | 21.96 |
As of June 30, 2026, Alebund Pharmaceuticals (Jiangsu) Limited Class H holds 1.61B in cash and equivalents against 666.47M in total debt, resulting in a net debt position of -890.83M. Total book value stands at 1.63B, with working capital of 1.47B providing operational flexibility.
| Cash & Cash Equivalents | 1.61B |
| Total Debt | 666.47M |
| Net Debt | -890.83M |
| Equity (Book Value) | 1.63B |
| Book Value Per Share | 4.79 |
| Working Capital | 1.47B |
Already premium?